In this study, Al18F-PSMA-BCH PET/CT will be performed in patients with prostate specific membrane antigen positive tumor, to evaluate the tumour detection efficacy of Al18F-PSMA-BCH PET/CT.
Patients with suspected or clearly diagnosed PSMA positive-expressing tumors, including prostate cancer, transitional epithelial carcinoma, colon carcinoma, adenoid cystadenocarcinoma, mesothelioma, hepatocellular carcinoma, cholangiocellular carcinoma, multiple myeloma, etc.
Age is 18 or older; No gender limitation.
Signed the informed consent.
Willing and able to cooperate with all projects in this study.
Patients with serious neurological diseases,or gastrointestinal tract disease, cardiovascular disease, liver disease, kidney disease, blood system disease, endocrine system disease, respiratory system disease, immune deficiency disease, etc
Claustrophobia.
Pregnant or lactation women.
Received experimental drug or device within 1 month.
Single group
Al18F-PSMA-BCH PET/CT
DrugPatients will be intravenously injected with Al18F-PSMA-BCH and undergo PET/CT scan.
Diagnostic value
Sensitivity and Specificity of 18F-PSMA PET / CT for the diagnosis of Prostate Specific Membrane Antigen Positive Tumor
Click on the lead sponsor to view all of their trials.
